$PTGX insider trading
Over the last 12 months, Protagonist Therapeutics insiders reported no purchases and 23 sales totaling $73.1M across SEC Form 4 filings. 30% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $73.1M 23 events
- Events · 12m
- 23 Form 4 filings, grouped
- Insiders · 12m
- 7 distinct reporters
- 10b5-1 share
- 30% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | PATEL DINESH V PH DPresident and CEO · O·D | ▼ Sale | 125,000 | $145.92 | $18.2M | -19.3% | plan · 3 tranches |
| Aug 11, 2026 | PATEL DINESH V PH DPresident and CEO · O·D | ▼ Sale | 100,000 | $148.91 | $14.9M | -16% | plan · 2 tranches |
| Jun 23, 2026 | Waddill William D.D | ▼ Sale | 9,000 | $117.94 | $1.1M | -53.5% | plan |
| Jun 10, 2026 | Waddill William D.D | ▼ Sale | 9,000 | $107.68 | $969K | -53.5% | plan |
| May 29, 2026 | Waddill William D.D | ▼ Sale | 9,000 | $99.64 | $897K | -53.5% | plan |
| May 8, 2026 | Giraudo BryanD | ▼ Sale | 18,000 | $100.05 | $1.8M | -100% | 2 tranches · indirect |
| May 8, 2026 | Giraudo BryanD | ▼ Sale | 41,130 | $100.12 | $4.1M | -76.4% | 2 tranches |
| Apr 20, 2026 | Ali AsifChief Financial Officer · O | ▼ Sale | 1,750 | $105.47 | $185K | -2.9% | — |
| Mar 26, 2026 | MOLINA ARTURO MDChief Medical Officer · O | ▼ Sale | 15,000 | $104.79 | $1.6M | -15.1% | — |
| Mar 26, 2026 | SELICK HAROLD ED | ▼ Sale | 24,000 | $105 | $2.5M | -28.3% | — |
| Mar 26, 2026 | Ali AsifChief Financial Officer · O | ▼ Sale | 24,765 | $104.24 | $2.6M | -29% | — |
| Mar 25, 2026 | PATEL DINESH V PH DPresident and CEO · O·D | ▼ Sale | 54,700 | $101 | $5.5M | -9.4% | 2 tranches |
| Feb 17, 2026 | Williams Lewis TD | ▼ Sale | 18,000 | $82.42 | $1.5M | -69.7% | — |
| Feb 6, 2026 | Waddill William D.D | ▼ Sale | 20,000 | $83.68 | $1.7M | -71.9% | — |
| Jan 27, 2026 | PATEL DINESH V PH DPresident and CEO · O·D | ▼ Sale | 48,273 | $84.18 | $4.1M | -7.8% | 4 tranches |
| Jan 27, 2026 | Ali AsifChief Financial Officer · O | ▼ Sale | 46,203 | $83.13 | $3.8M | -43.4% | 2 tranches |
| Jan 27, 2026 | MOLINA ARTURO MDChief Medical Officer · O | ▼ Sale | 23,151 | $82.3 | $1.9M | -21.6% | 3 tranches |
| Jan 20, 2026 | MOLINA ARTURO MDChief Medical Officer · O | ▼ Sale | 9,514 | $82.48 | $785K | -8.9% | — |
| Jan 20, 2026 | PATEL DINESH V PH DPresident and CEO · O·D | ▼ Sale | 34,438 | $82.48 | $2.8M | -5.6% | — |
| Jan 20, 2026 | Ali AsifChief Financial Officer · O | ▼ Sale | 8,588 | $82.48 | $708K | -9.9% | — |
| Nov 17, 2025 | MOLINA ARTURO MDChief Medical Officer · O | ▼ Sale | 2,712 | $84.77 | $230K | -3.2% | — |
| Oct 10, 2025 | Waddill William D.D | ▼ Sale | 12,000 | $81.62 | $979K | -70.1% | plan · 2 tranches |
| Sep 22, 2025 | Waddill William D.D | ▼ Sale | 4,000 | $64.25 | $257K | -43.8% | plan |
| Aug 27, 2025 | Waddill William D.D | ▼ Sale | 4,000 | $59.25 | $237K | -30.5% | plan |
Every $PTGX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Protagonist Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $PTGX feed.